TXG
10x Genomics, Inc. · Healthcare · Medical - Healthcare Information Services
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 153.99K | $11.76M | n/a | n/a |
| Q2 2026 | 113 | +6 | 98.93M | $3.79B | +15 | −8 |
| Q1 2026 | 109 | +3 | 94.02M | $1.99B | +12 | −10 |
| Q4 2025 | 107 | +3 | 97.86M | $1.59B | +4 | n/a |
| Q3 2025 | 19 | -2 | 71.88M | $839.83M | n/a | −3 |
| Q2 2025 | 19 | +1 | 64.66M | $748.72M | +2 | −1 |
| Q1 2025 | 15 | 0 | 30.56M | $266.82M | +1 | −1 |
| Q4 2024 | 15 | +1 | 24.83M | $356.61M | +3 | −2 |
| Q3 2024 | 13 | 0 | 22.71M | $512.82M | +1 | −1 |
| Q2 2024 | 13 | n/a | 21.07M | $409.76M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 9.31M | n/a | $181.15M | 1.6% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 2.87M | n/a | $55.90M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Baillie Gifford ✦ | 2.74M | n/a | $53.33M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 4 | Geode Capital Management ✦ (passive) | 1.77M | n/a | $34.49M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 1.36M | n/a | $26.47M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 991.05K | n/a | $19.28M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Capital World Investors ✦ | 793.30K | n/a | $15.43M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 334.39K | n/a | $6.50M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 315.18K | n/a | $6.13M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Renaissance Technologies ✦ | 210.20K | n/a | $4.09M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | PRIMECAP Management ✦ | 186.80K | n/a | $3.63M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 136.78K | n/a | $2.66M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 35.40K | n/a | $688,550 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 328 holders, 124.40M shares, $2.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.00K sh · $78,228
Director · 1.22K sh · $100,542
Director · 2.27K sh · $185,391
Director · 1.32K sh · $107,082
Director · 614 sh · $48,820
Director · 292 sh · $22,833
Officer, Director · 2.80K sh · $230,622
Officer, Director · 9.90K sh · $810,071
Officer, Director · 9.30K sh · $752,401
Officer, Director · 2.00K sh · $159,239
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology